Clinical Trial Update: An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib [Phase 2]

View source ↗

Summary

An open-label Phase 2 extension study to enable continued access to ruxolitinib for subjects previously enrolled in ruxolitinib trials.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Pancreatic Cancer, Colorectal Cancer (CRC) | Phase 2 | Status: ACTIVE_NOT_RECRUITING